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Abstract A desirable property of any dose-escalation strategy for phase I oncology
trials is coherence: if the previous patient experienced a toxicity, a higher dose is not
recommended for the next patient; similarly, if the previous patient did not experience
a toxicity, a lower dose is not recommended for the next patient. The escalation with
overdose control (EWOC) approach is a model-based design that has been applied in
practice, under which the dose assigned to the next patient is the one that, given all
available data, has a posterior probability of exceeding the maximum tolerated dose
equal to a pre-specified value known as the feasibility bound. Several methodological
and applied publications have considered the EWOC approach with both feasibility
boundsfixed and increasing throughout the trial.Whilst theEWOCapproachwithfixed
feasibility bound has been proven to be coherent, some proposedmethods of increasing
the feasibility bound regardless of toxicity outcomes of patients can lead to incoherent
dose-escalation. This paper formalises a proof that incoherent dose-escalation can
occur if the feasibility bound is increased without consideration of preceding toxicity
outcomes, and shows via simulation studies that only small increases in the feasibility
bound are required for incoherent dose-escalations to occur.
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Maximum tolerated dose · Phase I trials · Coherence
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1 Introduction
Phase I clinical trials mark the first experimentation of a new drug in a human popu-
lation. For cytotoxic anti-cancer drugs, the aim of a phase I trial is to gradually adapt
the dose level of the drug given to patients in order to identify the Maximum Toler-
ated Dose (MTD), defined as the largest dose that leads to unacceptable toxicity in a
target proportion, θ , of patients (Babb and Rogatko 2004). The rationale for targeting
such a dose is based on the assumption that higher doses will be more effective, yet
more toxic (Green et al. 2003), and that toxicity is tolerable for optimal anti-tumour
activity (Babb et al. 1998). Toxicities are graded according to the National Cancer
Institute’s Common Terminology Criteria for Adverse Events (NCI CTCAE) (NCI
2009), and are usually reduced to a single binary outcome, which denotes whether a
Dose-Limiting Toxicity (DLT) has occurred or not (Le Tourneau et al. 2009). There-
fore, for a pre-specified Target Toxicity Level (TTL) of θ , the definition of the MTD
can be expressed mathematically as
P (DLT | dose = MTD) = θ. (1)
Since an unknown portion of the dose range will be too toxic for patients, a dose-
escalation study is conducted, rather than randomly allocating patients over discrete
dose levels and then estimating the MTD (Demirhan and Demirhan 2015). Further-
more, sample sizes in phase I oncology trials are often very small, which means that
multiple testing procedures that incorporate dose-toxicity orders are not particularly
useful (Pigeot 2000). To avoid these issues, several Bayesian adaptive methods, which
sequentially recommend dose adaptations and borrow information from lower dose
levels and prior beliefs, have been proposed for conducting dose-escalation studies and
estimating the MTD (O’Quigley et al. 1990; Babb et al. 1998; Cheung and Chappell
2000). The escalation with overdose control (EWOC) approach (Babb et al. 1998) is
a Bayesian adaptive design that reduces the risk of overdosing patients by choosing
doses with a posterior probability of being above the true MTD equal to some value
known as a feasibility bound. The feasibility bound, denoted as α, controls how con-
servative dose-escalation during the trial is and was originally suggested to be fixed
throughout the trial. Several publications (Babb and Rogatko 2001; Cheng et al. 2004;
Tighiouart and Rogatko 2010) describe trials where α increases during the trial so that
eventually dose-selection is based on the posterior median of the MTD distribution; at
this point the posterior probability of dosing above the trueMTD is identical to dosing
below the trueMTD.Whilst such a design provides improved operating characteristics
relative to the EWOC approach with a fixed feasibility bound (Chu et al. 2009), there
is no guarantee of coherent dose-escalation (Cheung 2005; Tighiouart and Rogatko
2010; Cheung 2011) that is, dose escalation may be recommended despite having
observed a DLT in the previous patient.
This paper formalises a proof that incoherent dose-escalation can occur when the
feasibility bound is increased after observing toxicity in a dose-escalation trial using
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the EWOC approach. Along with a new theoretical result, several simulation studies
are conducted for a trial of 5-fluorouracil (5-FU) (Babb et al. 1998) using the EWOC
approach to see which situations are more likely to yield incoherent dose escalations
when the feasibility bound is increased during a trial. Recommendations for practical
implementation of the EWOC approach with a varying feasibility bound are provided
in the Discussion.
2 Escalation with overdose control
2.1 Overview
Let Yi be a binary random variable such that Yi = 1 if patient i experiences a DLT
and Yi = 0 otherwise. For a dose range of interest, bounded below by xmin and above
by xmax, denote the probability of DLT for patient i at dose level x ∈ [xmin, xmax] by
π (x;β), where β is a parameter vector. Several structural forms for π (x;β) have
been proposed (Cheung 2011), but we shall only consider the two-parameter logistic
model proposed in the original EWOC paper (Babb et al. 1998), i.e.
P (Yi = 1 | dose = x) = π (x;β0, β1) = exp (β0 + β1x)
1 + exp (β0 + β1x) , (2)
where β0 and β1 are parameters to be estimated and β1 > 0 to ensure the assumption
of monotonicity is satisfied (i.e. probability of DLT is non-decreasing with dose).
Rearranging Eq. 2 using Eq. 1, the MTD, denoted as γ , can be written as
γ = logit (θ) − β0
β1
. (3)
Under the original EWOC approach, π (x;β0, β1) is expressed in terms of two clini-
cally relevant parameters: theMTD γ (Eq. 3); and the probability of DLT at the lowest
dose level to be used in the trial, denoted as ρ0, where
ρ0 = π (xmin;β0, β1) = exp (β0 + β1xmin)
1 + exp (β0 + β1xmin) . (4)
We thereforewriteπ (x;β0, β1) asπ (x; γ, ρ0) and use aBayesian updating procedure
by placing prior distributions upon γ and ρ0 (Kadane et al. 1980); Babb et al. (1998)
suggest a Uniform prior distribution for γ over the interval [xmin, xmax], and aUniform
prior distribution for ρ0 over the interval [0, θ ], since ρ0 > θ implies that the MTD γ
is lower than xmin.
We condition all subsequent calculations on the event that Y1 = 0 (i.e. the first
patient did not experience a DLT; if Y1 = 1, then it is recommended that the trial is
suspended for safety concerns and the experimental dose range re-evaluated or the trial
terminated (Babb et al. 1998; Tighiouart et al. 2005; Tighiouart and Rogatko 2010)).
Given the set of trial data for n patients Dn = {(xi , yi ) : i = 1, . . . , n}, where patient
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i received dose xi ∈ [xmin, xmax] and had outcome yi ∈ {0, 1}, the joint likelihood
function for γ and ρ0 is
L (γ, ρ0|Dn) =
n∏
i=1
π (xi ; γ, ρ0)yi
[
1 − π (xi ; γ, ρ0)
]1−yi .
For some joint prior f (γ, ρ0) on parameters γ and ρ0 (we assume the aforementioned
independent Uniform priors; other frameworks are available (Tighiouart et al. 2005)),
we obtain the joint posterior distribution g (γ, ρ0 |Dn) via Bayes’ Theorem and hence
the marginal posterior cumulative distribution function (CDF) for the MTD γ is
Hn(γ





g(γ, ρ0 |Dn) dρ0 dγ. (5)
Dose allocation for future patients is determined by selecting the 100αth percentile
from the posterior MTD distribution, i.e. the dose for the (n + 1)th patient, denoted
xn+1, is xn+1 = H−1n (α). The constant α is defined as the feasibility bound and
governs the degree of conservatism present in the trial. The feasibility bound can be
interpreted via a decision-theoretic loss function, which describes the relative prefer-
ence of underdosing a patient compared to overdosing a patient. For some dose level
x and MTD γ , the loss function for feasibility bound α is
Loss(x, γ ) =
{
α(γ − x) if x is an underdose, i.e. x ≤ γ
(1 − α)(x − γ ) if x is an overdose, i.e. x ≥ γ. (6)
Equivalently, for any δ > 0, the loss incurred by overdosing a patient (with respect
to the MTD γ ) by δ units is 1−α
α
times greater than underdosing a patient by δ units
(Babb et al. 1998; Babb and Rogatko 2001). For α < 0.50, the loss function in Eq. 6
places a higher penalty on overdosing, whereas α = 0.50 penalises overdosing and
underdosing equally severely. We only consider the loss function given in Eq. 6 for
dose recommendations, though alternative myopic loss functions, or even balanced
loss functions (if we wished to estimate the dose-toxicity relationship in full as well
as identify the MTD) could be considered (Jozani et al. 2012).
2.2 Increasing the feasibility bound mid-trial
The idea of increasing the feasibility bound during the trial has been discussed (Babb
and Rogatko 2001, 2004) and used in practice (Babb and Rogatko 2001; Cheng et al.
2004; Tighiouart and Rogatko 2010). At the beginning of the trial α is set to some
minimal level strictly less than 0.50, so that the first patients that enter the trial are
treated at safe doses with a high probability. As data are accrued, one can afford to be
less conservative about dose-escalation, since the precision of the MTD distribution
is increasing. To facilitate this, α can be gradually increased towards 0.50, at which
point patients will be treated at the posterior median estimate of the MTD distribution.
With respect to the loss function in Eq. 6, when α tends towards 0.50, the implication
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is that investigators become less concerned with underdosing relative to overdosing;
when α = 0.50, the penalty for underdosing is identical to that of overdosing.
3 Coherence violations
For fixed α throughout the trial, the EWOC approach is coherent in escalation and
de-escalation (Tighiouart and Rogatko 2010). We show that for increases in α after
observing DLT outcomes, incoherent dose-escalation may occur.
3.1 Theoretical work
Let Hn(γ ) be the posterior CDF of the MTD parameter γ , as defined in Eq. 5. Define
αn to be the value of α used to choose the dose xn ∈ [xmin, xmax] for patient n.
Therefore Hn−1(xn) = αn ⇔ H−1n−1(αn) = xn . First, we recall what it means to be
coherent in dose-escalation.
Definition 1 (Coherent in dose-escalation) Let Hn(x) denote the posterior CDF of
the MTD parameter γ given trial data for the first n ≥ 2 patients. Assume Hn(x) is
well-defined and infinitely differentiable on (xmin, xmax). A dose-escalation design is
said to be coherent in dose-escalation if and only if xn+1 ≤ xn whenever yn = 1.
To show coherence in dose-escalation for the EWOC approach with fixed α, it is
sufficient to show Hn(x) ≥ Hn−1(x) for all x ∈ [xmin, xmax] and n ≥ 2.
Theorem 2 (Coherence of EWOC with fixed α) For αn = α ∈ [0, 1] for all n, when
yn = 1, Hn(t) ≥ Hn−1(t) for all t ∈ [xmin, xmax] ⇔ H−1n (α) ≤ H−1n−1(α) ⇔ xn+1 ≤
xn.
Proof See appendix of Tighiouart and Rogatko (2010) for proof. unionsq
We build upon this result to prove the possibility of incoherent dose-escalation
when the feasibility bound is increased following a patient experiencing a DLT.
Theorem 3 (Non-guarantee of coherence in escalation) Assume that H−1n (1) > xn,
where Hn(x) is as defined by Eq. 5 and Definition 1. Then there exists some α∗ > αn
such that H−1n (α∗) > H−1n−1(αn) when yn = 1.
Proof Both Hn(x) and Hn−1(x) are continuous and non-decreasing in x . By applying
Theorem 2 and the Intermediate Value Theorem, and given H−1n (1) > xn (i.e. xn <
inf {x : Hn(x) = 1}), there exists some α′ ≥ αn that must give H−1n (α′) = xn =
H−1n−1(αn). Furthermore, since Hn is continuous and non-decreasing, H−1n (α∗) >
H−1n (α′) for α∗ > α′, with equality existing if and only if limt→xn H ′(t) = ∞,
which violates the assumption that Hn(x) is infinitely differentiable on the interval
(xmin, xmax). Therefore, given H−1n (1) > xn , there exists an α∗ satisfying αn ≤ α′ <
α∗ ≤ 1 such that H−1n (α∗) > H−1n−1(αn) when yn = 1. unionsq
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Theorem 3 considers the case where H−1n (1) > xn , otherwise we are in the case
where H−1n (1) < H−1n−1(αn) = xn , and incoherent escalation is impossible for all
α ≥ αn . Whilst this is entirely plausible, Theorem 3 shows that there can still exist
instances whereby incoherent dose-escalation may occur. We explore this with a prac-
tical example in Sect. 3.2.
3.2 Practical example
Consider the trial described by Babb et al. (1998) that used the EWOC approach to
find the MTD of 5-fluorouracil (5-FU) when given in combination with 20mg/m2
leucovorin and 0.5mg/m2 topotecan to patients with malignant solid tumours. In this
trial, xmin = 140, xmax = 425 and θ = 13 . The dose-toxicity model in Eq. 2 was used
with γ ∼ U [xmin, xmax] and ρ0 ∼ U [0, θ ] a priori, and γ and ρ0 independent. For
this trial, α was fixed at 0.25 throughout. We simulate a trial of 40 patients, assuming
the trueMTDvalue (γ True) is 300mg/m2 and the true probability ofDLT at xmin (ρTrue0 )
is 0.08. We observe the minimum size difference between αn+1 and 0.25 required to
generate an incoherent dose-escalation, had an increasing feasibility bound approach
been implemented after patient n, via the following procedure:
1. Let n = 1 and α = 0.25. Dose patient 1 at x1 = xmin and let Y1 = 0 (otherwise
trial does not proceed).
2. For 2 ≤ n ≤ 40:
(a) Given trial data Dn−1 = {x1, y1, . . . , xn−1, yn−1}, dose patient n at the dose
recommended as per the standard EWOC approach (xn = H−1n−1(α)) and set
yn = 1.
(b) Obtain the posterior CDF for γ , Hn(γ ).
(c) Using Hn(γ ), find the minimum value of α ∈ A = {0.26, . . . , 0.50} that gives
an incoherent dose-escalation for patient n + 1, i.e.
αminn+1 = min
{
α ∈ A : H−1n (α) > xn
}
. (7)
(d) Record αminn+1 and re-generate Yn from the Bernoulli distribution with proba-
bility π(xn; γ True, ρTrue0 ).
(e) Repeat steps a)-d) with updated sample size n ← n + 1 and updated filtration
Dn ← {Dn−1, xn,Yn}.
Table 1 shows one simulated trial, with patient number, observed DLT outcome,
dose given and minimum feasibility bound required to guarantee incoherent dose-
escalation, should the DLT outcome of the previous patient actually be equal to 1. As
more patients are recruited into the trial, the value of αminn+1 tends to decrease. This is
because as more data are accrued, the variance around Hn(γ ) decreases and new data
provide smaller shifts in the position of Hn+1(γ ) relative to Hn(γ ). The same phenom-
enon will occur when strong prior distributions are placed on the model parameters
(see Sect. 3.3) and therefore αminn+1 for small n is more likely to be much lower than
the figures presented in Table 1. Although this is only one simulated trial, increases
in the feasibility bound by 0.04 or 0.05, which are increment sizes that have been
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Table 1 Minimum value of feasibility bound αminn+1 that leads to incoherent dose-escalation for patient
n+1 following n patients dosed under the original EWOC approach with fixed feasibility bound, assuming
that patient n has a DLT
Patient (n) DLT Dose αminn+1 Patient (n) DLT Dose αminn+1
1 0 140 – 21 1 279 0.32
2 0 211 0.50 22 1 268 0.32
3 0 243 0.44 23 0 258 0.32
4 0 261 0.39 24 1 260 0.30
5 0 276 0.39 25 0 252 0.32
6 0 290 0.37 26 1 257 0.32
7 0 300 0.37 27 1 246 0.31
8 0 311 0.34 28 0 238 0.30
9 0 319 0.35 29 0 243 0.32
10 0 328 0.35 30 1 245 0.30
11 1 336 0.34 31 1 237 0.32
12 0 320 0.35 32 1 229 0.30
13 1 328 0.36 33 0 223 0.31
14 1 311 0.33 34 1 225 0.31
15 0 297 0.33 35 0 219 0.30
16 0 303 0.33 36 0 222 0.31
17 1 310 0.34 37 1 224 0.30
18 1 297 0.33 38 1 217 0.31
19 0 285 0.32 39 0 212 0.31
20 1 290 0.32 40 0 214 0.29
Actual DLT outcomes from simulated trial also given to show progression under EWOC approach with
fixed feasibility bound
used in actual trials (Tighiouart and Rogatko 2010), generate incoherent escalations in
patients recruited into the trial later on. We now conduct several simulation studies to
explore how the number of dose levels available and the strength of prior probability
distributions affect the distribution of αminn+1.
3.3 Simulation studies
To investigate the required increase in the feasibility bound to yield incoherent dose
escalations, simulation studies for six different EWOC trial setups were conducted
(Table 2). Scenario 1 is identical to the setup specified in Sect. 3.2, and scenarios 2,
3 and 4 are the same as scenario 1, but with discrete dose levels at different intervals.
Scenarios 5 and 6 are the same as scenario 1, except the priors are specified differently;
scenario 5 has skewed priors that placemoreweight on theMTDbeing at the lower end
of the dose range, whereas scenario 6 is a strong prior that assumes the MTD is in the
middle of the dose range.Both of these scenarios dependonBeta prior distributions that
assume an effective sample size of 10 patients (calculated by summing the parameters
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Table 2 Scenarios for simulation study, including number of dose levels and prior distributions
Scenario Number of dose levels f (γ ) f (ρ0)
1 286 (every 1mg/m2) U [xmin, xmax] U [0, θ ]
2 20 (every 15mg/m2) U [xmin, xmax] U [0, θ ]
3 16 (every 19mg/m2) U [xmin, xmax] U [0, θ ]
4 6 (every 57mg/m2) U [xmin, xmax] U [0, θ ]
5 286 (every 1mg/m2) xmin + (xmax − xmin) × Beta [3, 7] θ × Beta [7, 3]
6 286 (every 1mg/m2) xmin + (xmax − xmin) × Beta [5, 5] θ × Beta [5, 5]
of the Beta distribution). For each scenario, 100 trials were simulated using the same
procedure specified in Sect. 3.2. Figure 1 shows the mean and 95% credible intervals
for the distribution ofαminn+1 as the trial progresses for all six scenarios. Across scenarios
1, 2, 3 and 4, themean trajectory of αminn+1 over the trial differs depending on the number
of dose levels; on average, larger increases in the feasibility bound are required to
generate incoherent dose escalations as the number of available dose levels decreases.
The 95% credible intervals are wider when fewer dose levels are available; this is
because there are fewer instances when incoherent dose escalations arise when the
feasibility bound can reach at most 0.50. Scenarios 2, 3 and 4, where 20, 16 and
six evenly-spaced discrete dose levels are used respectively, show the mean of αminn+1
to decrease to around 0.40 for most of the trial (scenario 4 95% CI (0.30, 0.49)),
whereas scenario 1 shows a gradual mean decrease to 0.32 at patient 40 (95% CI
(0.29, 0.36)). This means that upon observing a DLT after patient n in a trial, increases
in the feasibility bound by 0.04 or 0.05 could be enough to provide an incoherent dose
escalation for patient n + 1; in scenario 4 this occurs before patient 10, meaning that
patients recruited at the start of the trial could be recommended an increase of at least
57mg/m2 even after observing a DLT in the previous patient. Under scenarios 5 and 6,
which used strong skewed and strong symmetric priors respectively, small increases
in the feasibility bound are required to generate an incoherent dose-escalation even
early on in a trial; at patient 10, the mean of αminn+1 is 0.30 (95% CI (0.28, 0.33)). This
is because the change in the posterior cumulative distribution function of the MTD
after incorporating new data is much smaller when stronger priors are used.
4 Discussion
This paper formally outlines how incoherent dose-escalation can occur in phase I
oncology trials when increasing the feasibility bound after observing toxicity under the
EWOC approach. The example presented in Sect. 3.2 shows that even small increases
in the feasibility bound can be enough to cause incoherent dose-escalation. The simu-
lation studies presented in Sect. 3.3 also indicate that this is the case for different dose
ranges and prior specifications. Interestingly, small changes in the feasibility bound
could lead to incoherent dose-escalations being recommended early on in the trial, par-
ticularly if strong priors are used or few dose levels are considered. The key message
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Fig. 1 Distribution of minimum feasibility bounds causing incoherence (αminn+1) over patient number for
scenarios 1–6.Number of trials at patients 10, 20, 30 and 40 that yieldedαminn+1 within the interval [0.26, 0.50]
shown in parentheses
is that incoherence can occur and that a design’s operating characteristics and chance
of permitting incoherent escalation should be fully determined before an actual trial
is conducted. Arbitrary increases in the feasibility bound as per the trials referenced
in Sect. 2.2 are best avoided by escalating the feasibility bound only in the absence
of DLTs, thus guaranteeing coherent dose-escalation and de-escalation. However, this
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should not exclude investigators from assessing how a trial design may perform for
increases in the feasibility bound; large changes in αn increase the risk of patients
experiencing severe toxicity. The approach for changing the feasibility bound should
ideally be specified before the trial begins; ad hoc changes to the planned increases
in the feasibility bound during the trial could result in a poor understanding of the
design’s future behaviour, and on a practical level, require changes in the trial proto-
col to bemade. Equally, one would be choosing the feasibility bound based on the dose
that they wanted to use, rather than considering where it is on the MTD distribution.
Before the trial, one may run simulation studies similar to those in Sect. 3.3 in order to
determine how large increases in the feasibility boundmight affect the dose-escalation
behaviour of a trial design. This can be undertaken for trials with continuous or dis-
crete doses, strong or weak priors, and can help clinicians determine when in the trial
to reduce how conservative they wish to be in dose escalation. The results of this work
show that in some scenarios, the feasibility bound need not increase by a lot before an
incoherent escalation is observed, which suggests it is safer to increase the feasibility
bound only in the absence of toxicity, whilst still converging to the MTD (Zacks et al.
1998). Bartroff and Lai (2011) have previously considered the frequency of coherence
violations under the EWOC design with increasing feasibility bounds, yet focused on
the ability of the model to recommend the correct MTD and other operating charac-
teristics. Whilst designs with superior operating characteristics with respect to patient
safety and accurate MTD estimation are to be encouraged in practice, ensuring that
incoherent dose escalation is not possible should also be a priority to prevent unsafe
dose escalations being recommended and reduce the risk of having to make unex-
pected changes to the design mid-trial. Even for approaches that converge to the true
MTD, the fluctuation of the dose level around and above the true MTD means that
incoherent escalations may occur at both low and high dose levels. Therefore, there
is a risk of escalating the dose to a severely toxic level when the feasibility bound is
increased after observing a DLT, and this can be from either a tolerable or intolerable
dose.
It should be made explicit that this work is not a refutation of the EWOC approach,
or indeed a call to prevent changing the feasibility bound mid-trial. Model-based
adaptive designs for phase I trials, many of which have been shown to supersede the
traditional 3 + 3 approach (Carter 1973; Storer 1989) have been carefully developed
over the last 25years (Le Tourneau et al. 2009), and much work has been done to
increase their prevalence in clinical practice. The EWOC approach is a welcome
addition to the family of model-based designs and increasing the feasibility bound
during a trial is a sensible idea in order to escalate towards the true MTD faster than
usual whilst mitigating the risk of overdosing patients. Whatever the choice of dose-
escalation design, operating characteristics should be well-assessed and compared to
other available approaches, and should be done so on a trial-by-trial basis.
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